This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 643597.
ClinicalTrials.gov Identifier:
NCT02527629
News
Newly developed method helps to quantify the residual immunogenic potential of decellularized human heart valves
Dot-blot techniques demonstrate highly individual immune response towards decellularized homografts - Results published Open Access in the European Journal of Cardio-Thoracic-Surgery
Results of the first 106 pediatric patients published– Open Acces in the European Journal of Cardio-Thoracic Surgery
The results of the first 106 pediatric implantations of a decellularised aortic homograft have been published now and are available Open Access under this permanent link:
Initial results of the ARISE trial published in the European Journal of Cardio-Thoracic Surgery – Open Acces
Initial results from the ARISE trial, a prospective, single-arm European study on decellularized allografts for aortic valve replacement now have been published and are available Open Access under this permanent link:
Welcome to ARISE
65,000 aortic valve replacements (AVR) are performed in Europe each year to treat acquired and congenital aortic valve diseases. Current AVR options are, however, limited for young patients - especially female patients - and those unwilling to accept life-long medical anticoagulation with its inherent risks. None of the currently available prostheses for AVR is tailored toward the individual patient or allows for individual regeneration. The ARISE project will bridge this therapeutic gap in a clinical study to determine the feasibility, safety and efficacy of regenerative heart valves for aortic valve replacement.